EBO Stock Overview

Engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. More details

EBO fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	1/6
Past Performance	3/6
Financial Health	3/6
Dividends	4/6

Rewards

Trading at 23.6% below our estimate of its fair value

Earnings are forecast to grow 6.76% per year

Earnings grew by 7.2% over the past year

Risk Analysis

Has a high level of debt

Dividend of 3.43% is not well covered by free cash flows

My Notes

Capture your thoughts, links and company narrative

EBOS Group Limited Competitors

Paragon Care

ASX:PGC

AU$819.4m

Ramsay Health Care

ASX:RHC

AU$7.9b

Sonic Healthcare

ASX:SHL

AU$13.0b

Ansell

ASX:ANN

AU$4.8b

Price History & Performance

Summary of share price highs, lows and changes for EBOS Group
Historical stock prices
Current Share Price	NZ$33.13
52 Week High	NZ$35.31
52 Week Low	NZ$28.75
Beta	0.25
1 Month Change	-1.90%
3 Month Change	-3.80%
1 Year Change	1.78%
3 Year Change	-11.24%
5 Year Change	48.83%
Change since IPO	97.67%

Recent updates

Shareholder Returns

	EBO	AU Healthcare	AU Market
7D	-0.5%	-4.4%	-2.7%
1Y	1.8%	-7.5%	6.5%

Return vs Industry: EBO exceeded the Australian Healthcare industry which returned -7.5% over the past year.

Return vs Market: EBO underperformed the Australian Market which returned 6.5% over the past year.

Price Volatility

Is EBO's price volatile compared to industry and market?
EBO volatility
EBO Average Weekly Movement	2.5%
Healthcare Industry Average Movement	5.6%
Market Average Movement	8.0%
10% most volatile stocks in AU Market	16.8%
10% least volatile stocks in AU Market	3.1%

Stable Share Price: EBO has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: EBO's weekly volatility (2%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1922	4,557	John Cullity	www.ebosgroup.com

EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and health communications, programs, and consultancy services.

EBOS Group Limited Fundamentals Summary

How do EBOS Group's earnings and revenue compare to its market cap?
EBO fundamental statistics
Market cap	AU$6.45b
Earnings (TTM)	AU$271.55m
Revenue (TTM)	AU$13.19b

23.7x

P/E Ratio

0.5x

P/S Ratio

Is EBO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EBO income statement (TTM)
Revenue	AU$13.19b
Cost of Revenue	AU$11.56b
Gross Profit	AU$1.63b
Other Expenses	AU$1.36b
Earnings	AU$271.55m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	1.39
Gross Margin	12.38%
Net Profit Margin	2.06%
Debt/Equity Ratio	51.1%

How did EBO perform over the long term?

See historical performance and comparison

Dividends

3.4%

Current Dividend Yield

78%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/21 12:11
End of Day Share Price	2024/12/20 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

EBOS Group Limited is covered by 16 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Saul Hadassin	Barrenjoey Markets Pty Limited
Benjamin Brayshaw	Barrenjoey Markets Pty Limited
Lyanne Harrison	BofA Global Research

EBO Stock Overview

Rewards

Risk Analysis

EBOS Group Limited Competitors

ASX:PGC

AU$819.4m

ASX:RHC

AU$7.9b

ASX:SHL

AU$13.0b

ASX:ANN

AU$4.8b

Price History & Performance

Recent News & Updates

EBOS Group Limited Announces the Retirement of Peter Williams as Director

Final dividend of NZ$0.64 announced

EBOS Group Limited Announces Final Dividend, Payable on 18 September 2024

Full year 2024 earnings released: EPS: AU$1.41 (vs AU$1.33 in FY 2023)

EBOS Group Limited Announces Chief Financial Officer Changes

Insider recently sold AU$4.9m worth of stock

Recent updates

EBOS Group Limited Announces the Retirement of Peter Williams as Director

Final dividend of NZ$0.64 announced

EBOS Group Limited Announces Final Dividend, Payable on 18 September 2024

Full year 2024 earnings released: EPS: AU$1.41 (vs AU$1.33 in FY 2023)

EBOS Group Limited Announces Chief Financial Officer Changes

Insider recently sold AU$4.9m worth of stock

First half dividend of NZ$0.60 announced

First half 2024 earnings released: EPS: AU$0.71 (vs AU$0.70 in 1H 2023)

EBOS Group Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Now 20% undervalued

EBOS Group Limited to Report First Half, 2024 Results on Feb 21, 2024

EBOS Group Limited (NZSE:EBO) acquired additional 39% stake in Transmedic Pte Ltd. from TS Lee for approximately SGD 120 million.

Paragon Care Reportedly Taps Rothschild for Defence Amid Buyout Talk

Now 23% undervalued

EBOS Reportedly Runs Eye over Paragon Care after Abandoning Greencross Pursuit

EBOS Not to Proceed with Acquisition in Animal Care Segment

EBOS Not to Proceed with Acquisition in Animal Care Segment

Now 21% undervalued

EBOS Group Limited Announces Fully Franked Ordinary Dividend for the Six Months Ended June 30, 2023, Payable on 29 September, 2023

Now 21% undervalued

Upcoming dividend of NZ$0.60 per share at 3.0% yield

Ebos Group Limited Announces Dividend, Payable on 29 September 2023

Full year 2023 earnings released: EPS: AU$1.33 (vs AU$1.15 in FY 2022)

Investor sentiment deteriorates as stock falls 18%

Now 26% undervalued after recent price drop

First half 2023 earnings released: EPS: AU$0.70 (vs AU$0.61 in 1H 2022)

EBOS Group Limited to Report Q2, 2023 Results on Feb 22, 2023

EBOS Group Limited Announces the Appointment of Mark Bloom as an Independent Director, Effective 16 September 2022

Upcoming dividend of NZ$0.51 per share

Full year 2022 earnings released: EPS: AU$1.15 (vs AU$1.13 in FY 2021)

EBOS Group Limited Announces Dividend for the Six Months Ended June 30, 2022, Payable on 30 September, 2022

Upcoming dividend of NZ$0.49 per share

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

EBOS Group Limited Announces Fully Franked Ordinary Dividend for the Six Months Ended December 31, 2021, Payable on March 18, 2022

Ebos Group Limited Announces Resignation of Nick Dowling as Director

Independent Director recently bought AU$55k worth of stock

EBOS Group Limited Announces Supplementary Dividend for the Six Months Ended June 30, 2021, Payable on Sept. 24, 2021

Upcoming dividend of NZ$0.48 per share

EBOS Group Limited (EBOS) acquired Sentry Medical.

Full year 2021 earnings released: EPS AU$1.13 (vs AU$1.01 in FY 2020)

EBOS Group Limited (NZSE:EBO) acquired Pioneer Medical Limited for AUD 40 million.

Upcoming Dividend of NZ$0.44 Per Share

Revenue beats expectations

First half 2021 earnings released: EPS AU$0.57 (vs AU$0.51 in 1H 2020)

EBOS Group Limited (NZSE:EBO) acquired Vet Distribution Business of Clifford Hallam Healthcare Pty Ltd for AUD 9.2 million.

EBOS Group Limited (NZSE:EBO) acquired CH2 Vet for AUD 9.2 million.

New 90-day high: AU$28.30

EBOS Group Limited, Annual General Meeting, Oct 19, 2021

New 90-day high: AU$28.29

New 90-day high: AU$25.38

EBOS Group Limited (NZSE:EBO) entered into an agreement to acquire Cryomed Aesthetics Pty Limited for AUD 14.1 million.

New 90-day high: AU$23.21

New 90-day high - AU$22.30

New 90-day high - AU$21.36

Full year earnings released

New 90-day low - AU$20.17

Shareholder Returns

Price Volatility

About the Company